Novartis Q1 profit down on US generic erosion

Swiss drugmaker Novartis reported first-quarter core operating profit below market expectations on Tuesday, as generic competition for its top-selling heart drug Entresto weighed on sales.

Quarterly group operating income, adjusted for special items, came in at $4.9 billion, below average analyst expectations of about $5.1 billion cited by Visible Alpha.